The U.S. Food and Drug Administration approved Vanda Pharmaceuticals’ oral drug Nereus (tradipitant), marking the first new prescription treatment for motion sickness in more than four decades. Vanda announced the approval based on three pivotal studies, including two phase III trials conducted in real-world boat environments. The company signaled a near-term commercial launch and the approval triggered a sharp uptick in stock price.